A woman in her mid-30's with salt-losing 21-hydroxylase deficiency diagnosed in neonatal period had been supplemented gluco-and mineralocorticoids before she quit the regimen because of steroid-induced obesity. After quitting, she was referred to the author. Review of endocrine records in preceding two years revealed hyper-reninemic hyperaldosteronism without hypertension and hypokalemia. Because of stubborn refusal to continue the supplementation of gluco-and mineralo-corticoids, she was allowed to be off the supplementation for two months after possible consequences were explained. When she returned two months later, she was normotensive and normokalemic in the face of hyperaldosteronemia.
been supplemented with varying doses of Dexamethasone and FC in subsequent two-year period (vide infra) before she quit his care because of being intolerant of steroid-associated obesity. She returned to the pediatric endocrinologist, who asked the author to take over her care. At the time of the transfer to the author, the patient brought in two sets of documents, i.e., narrative summary of an endocrine history of 32 years from her neonatal period by the pediatric endocrinologist and data sheets of subsequent two years under the second endocrinologist's care.
In the first document, following items were depicted: she was born with a weight of 2,420 grams with ambiguous genitalia; her serum sodium concentration was 121, 125 mEq/L and potassium 5.4 ～ 8.0 meq/L two weeks after birth; a gas chromatographic study of urinary steroids was reportedly consistent with 21-hydroxylase deficiency. In the second document, data of blood tests related to corticosteroids and corticosteroid supplementation had been recorded in a chronological order. The author re-arranged these data in reference to corticosteroid regimens in five periods 1 through 5 (Table 1) . From table 1 it was learned that ACTH level was brought in the recommended range of the guideline of 21-OHD management [1] in Period 5 where in regimen of dexamethasone 0.875 mg/day without FC was employed. Normokalemia had been maintained in the presence of high plasma renin activities and normal or high aldosterone levels by supplementation with either 0.025 or 0.05 μg of FC per day in Periods
Background
Almost three decades have elapsed since congenital adrenal hyperplasia was included in neonatal screening program in Japan. Many patients with this disorder supposedly have reached adulthood. Problems related to care transfer from pediatric endocrinologists were recently reviewed by Auchus RJ, et al. [1] , who wrote the goal of mineralocorticoid replacement [for grownup patients with salt-losing 21-hydroxylase deficiency (21-OHD)] is to maintain plasma renin activity as low as possible without causing hypertension, hypokalemia, orthostatic hypotension, or salt craving [sic] . As for mineralocorticoid supplementation in adult patients with 21-OHD, the panel of the recent diagnostic and management guideline of The Endocrine Society write as follows: the optimal dose of Fludrocortisones (FC) supplementation in adult patients with 21-OHD has not been critically studied; most non-hypertensive adults with 21-OHD benefit from continued mineralocorticoid treatment; maintenance treatment of FC of 0.05 to 0.2 mg per day is suggested [2] .
Case Presentation
The patient with 21-hydroxylase deficiency (vide infra) was 34 years old when her endocrine care was asked by a pediatric endocrinologist of her childhood. He had treated the patient with varying doses of Hydrocortisone (HC) and FC until her care was transferred to an endocrinologist at the age of 32 years. Then, she had When seen by the author first time, her height was 151 cm, weight 75.5 kg, body mass index 33.1 kg/m 2 . She had been normotensive and amenorrheic after discontinuing the supplementation of corticosteroid. She initially agreed to the author's proposal to keep supplementation consisting of HC 15 mg in three unequally divided doses and FC 0.05 mg per day. Nevertheless, she soon quit taking both apparently without overt ill effects. Her weight reduced to 70 kg. After being explained about possible consequences of withholding HC and FC, she opted staying being off HC and FC for subsequent two months. She was advised to keep salt intake sufficiently and to take HC 10 to 20 mg/day on days when she foresees physical or psychosocial stress. This trial was in part aimed to convince her of the importance of continuing the supplementation.
Sci Forschen
When she returned to the clinic two months later, her weight reduced to 64 kg (BMI 28.1 kg/m 2 ) and her blood pressure was ranging from 120-130/70-80 mmHg. Serum electrolytes, creatinine, and hormones related to pituitary-adrenal axis of this period (period 6) were shown in table 2: the serum sodium and potassium were in the normal ranges; ACTH level was elevated; serum cortisol level was subnormal and urinary excretion of cortisol was borderline low; both serum and urinary excretion of aldosterone were elevated.
Since then, she has been kept off corticosteroid supplementation. Repeated studies of chemistry and hormone of blood and urine revealed results similar to those of the first study (Table 2, Period 7). The results of another study done two years later were also similar and the progesterone level, 36.9 ng/ml, was in the ranges of pregnant women ( Table 2 , Period 8, progesterone measured instead of 17-OHP because of the manufacturer's cancellation of the release of 17-OHP assay kit in September, 2008). She has had no menstrual periods while not being supplemented with glucocorticoid. Up to the present, she has been allowed to be free of corticosteroid supplementation, instructed to have sufficient salt intake, and advised to take 10 to 20 mg HC only on days when she foresees physical or psychosocial stress.
Studies of chemistry and hormone of blood and urine were repeated twice ( Table 2 , Periods 8 and 9). The results of electrolytes and creatinine of this period were similar to those of other periods. An arterial gas analysis revealed pH 7.40, pO 2 93 mmHg, pCO 2 35.6 mmHg, and bicarbonate 21.7 mmol/l. (obtained between period 6 and period 7). In this period, urine was acidic and urine showed positive anion gap (Table 2) , an indirect measure of ammonium ion in urine [3] .
The measurements of ACTH, plasma rennin activity, plasma aldosterone concentration, urinary concentrations of cortisol and aldosterone were performed by Biomedical Laboratory (BML, Saitama, Japan).
Discussion
Although the account of her neonatal period is suggestive of salt wasting 21-OHD, her current phenotype appears consistent with of simple virilizing 21-OHD. The gene analysis of CYP21A2 has not been done.
In this patient, cortisol levels and urinary excretion of cortisol of this patient were in low-normal range in periods 6 and 7 ( Table  2 ). Her cortisol production has apparently ameliorated modestly by overproduction of ACTH over many years. As the secretory rate of aldosterone is three-order magnitude less than that of cortisol, i.e. 1.5-12.5 μg/day (excretion rate, without salt restriction) [4] vis. 9.9 ± 2.7 mg/day (production rate) [5] , the recovery of aldosterone production could be understood. Another explanation of aldosterone production in patients with 21-OHD is provided by Gomes and coworkers [6] , i.e. aldosterone is synthesized from 21-hydroxylation of progesterone (not from 17-OHO) by hepatic enzymes, CYP2C19 and CYP3A4, though less efficiently than CYP21A, in five children with 21-OHD.
Despite hyperaldosteronemia and hyperaldosteronuria, she had neither hypertension nor hypokalemia. Serum aldosterone levels and urinary excretion of aldosterone were more than the reference values in recent years ( Table 2 ). An arterial gas analysis revealed compensated mild metabolic acidosis. Acidic urine and positive urine anion gap were against distal renal tubular acidosis. Hence, hyperaldosteronism reportedly associated with distal renal tubular acidosis [7] is unlikely responsible in this patient. During pregnancy, elevated plasma renin activity [8, 9] and increase in plasma levels of progesterone and aldosterone [10, 11] have been known. The patient's plasma renin activity and levels of aldosterone and progesterone were elevated to the similar magnitude as those described in the literature [11] . Antagonistic activity of progesterone and 17-OHP against aldosterone receptor is shown in COS-7 cells, a cell line derived from African green monkey kidney, transfected with human mineralocorticoid receptor DNA [12] . Development of hypertension and hypokalemia appears to be prevented by overproduction of 17-OHP and progesterone.
Sci Forschen
Development of adrenal adenoma manifested by Cushing syndrome was reported in a young woman with late onset of 21-OHD, who had been treated as polycystic ovary syndrome without supplementation of gluco-and mineralo-corticoid [13] . If serum cortisol and aldosterone levels of this patient further increase, the image study of the adrenals would be necessary. The long-term outcome of persistent amenorrhea conceivably attributable to unsuppressed progesterone production needs to be clarified.
Though she has been not supplemented with gluco-and mineralocorticoid unless she foresees physical or psychosocial stress, she is provided with several days' supply of hydrocortisone in case of need and instructed to carry medical alert card depicting the diagnosis as well as treatment at acute care facilities.
Conclusion
An adult woman with salt-losing 21-OHD diagnosed in neonatal period remained normotension and normokalemia without gluco-and mineralo-corticoid supplementation in the face of hyper-reninenia and hyperaldosteronemia suggestive of aldosterone resistance presumably resulting from unsuppressed progesterone secretion. Long-acting glucocorticoid of a dose sufficient to suppress secretion of ACTH, progesterone and 17-OHP could partially ameliorate renin and aldosterone secretion in a tradeoff of intact menstruation and steroid-induced obesity. Optimal treatment of 21-OHD of grownup remains to be a difficult issue.
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